Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Eyenovia, Inc.
  6. Company
    EYEN   US30234E1047

EYENOVIA, INC.

(EYEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Eyenovia, Inc. is a clinical stage ophthalmic company. The company is developing a pipeline of therapeutics based microdose array print (MAP) platform technology. Its pipeline is focused on the late-stage development of microdosed medications for progressive myopia, presbyopia, and mydriasis. MydCombi is a combination micro-formulation product (phenylephrine-tropicamide) candidate for pharmacologic mydriasis (eye dilation). MicroPine is a topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching. MicroLine is a candidate, which is developing microdosed version of pilocarpine, a well understood ophthalmic medication that can dose-dependently induce miosis, or a contraction of the pupil.

Number of employees : 34 people.
Sales per Business
20192020Delta
Ophthalmic Pharmaceutical Agents--2.00100%-
USD in Million
Sales per region
20192020Delta
United States--2.00100%-
USD in Million
Managers
Name Title Age Since
Sean Ianchulev, Dr. President, CEO, Director & Chief Medical Officer 46 2014
John P. Gandolfo Chief Financial Officer & Secretary 59 2017
Luke Clauson VP-Engineering, Research & Development 42 2017
Jennifer Clasby VP-Clinical Operations & Regulatory Affairs 66 -
Michael M. Rowe Chief Operating Officer & VP-Commercial 58 2021
Fredric N. Eshelman, Dr. Chairman 72 2018
Ernest Mario, Dr. Independent Director 81 2014
Kenneth B. Lee Independent Director 72 2018
Charles E. Mather Independent Director 60 2018
Anthony Y. Sun, Dr. Independent Director 48 2018
Members of the board
Name Title Age Since
Fredric N. Eshelman, Dr. Chairman 72 2018
Sean Ianchulev, Dr. President, CEO, Director & Chief Medical Officer 46 2014
Curt H. LaBelle, Dr. Non-Independent Director 49 2014
Ernest Mario, Dr. Independent Director 81 2014
Kenneth B. Lee Independent Director 72 2018
Charles E. Mather Independent Director 60 2018
Anthony Y. Sun, Dr. Independent Director 48 2018
Julia A. Haller, Dr. Independent Director 65 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 25,947,832 16,545,598 63.8% 0 0.0% 63.8%
Shareholders
NameEquities%
Stuart M Grant 4,389,783 16.9%
Senju Pharmaceutical Co., Ltd. 1,738,566 6.70%
Fredric N. Eshelman 1,292,787 4.98%
The Vanguard Group, Inc. 722,576 2.78%
Sabby Capital LLC 608,720 2.35%
Private Medical Equity LLC 606,667 2.34%
Uniplan Investment Counsel, Inc. 591,942 2.28%
Sean Ianchulev 549,895 2.12%
Medical Strategy GmbH 394,493 1.52%
Ernest Mario 375,743 1.45%
Company contact information
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017

Phone : +1.917.289.1117
Web : http://www.eyenovia.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Eyenovia, Inc.
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
EYENOVIA, INC.-12.54%138
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657
MERCK & CO., INC.-4.24%198 283
ABBVIE INC.2.03%193 205
ASTRAZENECA PLC20.08%187 492
NOVARTIS AG-8.03%186 330
BRISTOL-MYERS SQUIBB COMPANY-5.92%129 683
SANOFI6.53%122 086
AMGEN INC.-9.60%118 022
GLAXOSMITHKLINE PLC4.29%96 396
ALLERGAN PLC0.97%63 659
CHUGAI PHARMACEUTICAL CO., LTD.-27.49%57 462
BAYER AG-0.56%54 575
JIANGSU HENGRUI MEDICINE CO., LTD.-46.12%49 566
DAIICHI SANKYO COMPANY, LIMITED-16.76%49 400
TAKEDA PHARMACEUTICAL COMPANY LIMITED-13.93%44 517
ASTELLAS PHARMA INC.25.60%32 494